Healthcare industry accounts for 88 percent of all ransomware attacks

In the newly released Security Engineering Research Team (SERT) Quarterly Threat Report for Q2 2016, Solutionary, a digital security company, analyzed the rates of ransomware attacks in all industries. Unsurprisingly, the healthcare industry topped the list.

In all industries analyzed the healthcare industry accounted for 88 percent of all ransomware attacks in Q2. The next highest effected industry was education with 6 percent, followed by finance at 4 percent.

“Healthcare has been a target for ransomware campaigns because the industry has often paid ransom to retrieve vital customer data quickly. Furthermore, healthcare organizations use an abundance of systems and devices that are crucial pivot-points for an attacker, and they can even be victims of ransomware themselves,” said Rob Kraus, director of research, Security Engineering Research Team, Solutionary. “The most important steps in protecting your company’s and your customers’ data from the growing malicious ransomware onslaught are ensuring that you have a robust backup and recovery process, and that your security software is up-to-date and able to detect the most recent ransomware variants. As the threat continues to evolve, it will be crucial for organizations to have defined incident-response procedures and proper detective and preventive controls in place to reduce ransomware’s impact.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.